Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWDoxofylline is a methylxanthine bronchodilator.1 It inhibits phosphodiesterase 2A1 (PDE2A1) and is an adenosine A2A receptor antagonist (IC50s = 0.74 and 0.9 mM, respectively).2 Doxofylline (10 µM) reduces superoxide production induced by LPS or PMA (Item No. 10008014) in isolated human monocytes.3 It delays platelet-activating factor-induced bronchoconstriction in isolated guinea pig lungs when used at concentrations ranging from 0.28 to 1.5 mM. Doxofylline (1 mg/kg) inhibits LPS-induced neutrophil recruitment to the lungs and IL-6 and TNF-α release into bronchoalveolar fluid (BALF) in mice.4
WARNING This product is not for human or veterinary use.
1. Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF. Eur. J. Pharmacol. 165(2-3), 269-277 (1989).
2. The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. Pulm. Pharmacol. Ther. 25(1), 55-61 (2012).
3. Comparison of anti-
4. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm. Pharmacol. Ther. 27(2), 170-178 (2014).